[1] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Evinacumab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 362-364.
|
[2] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Inclisiran
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 365-368.
|
[3] |
WANG Qi, ZOU Yunzeng.
New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 369-372.
|
[4] |
CHANG Shufu .
Progress of medical treatment of coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
|
[5] |
WANG Ruijie, WANG Liang, XU Dan, ZHOU Miaomiao, LI Jiming.
Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 409-417.
|
[6] |
YAN Lei, JIANG Haibin, NAFEISHA Paerhati, REZIWANGULI Yikemu, GENG Boyu, MAIERHABA Maimaitiaili.
Effects of different doses of dexmedetomidine on non-cardiac surgery stress and postoperative sleep in patients with coronary heart disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1340-1346.
|
[7] |
LU Xiya, LI Yuxing, LI Wenzhi, PENG Yuanyuan, HU Yi, WAN Li, CHEN Bilian.
Analysis of prescribing of antiplatelet drug in patients with coronary heart disease in department of geriatrics
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1285-1291.
|
[8] |
YUE Ling, DU Junhong, LIU Xiao, LI Yulan, XU Feixue.
Mechanisms of histone methylation and acetylation modifying enzymes in ovarian cancer and therapeutic advances
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1299-1306.
|
[9] |
CHEN Lifang, WANG Bo, WANG Weirong.
Research advances of histone deacetylase 3 in cardiovascular diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 88-97.
|
[10] |
ZHANG Mingqing,LIU Lingjuan,TIAN Jie.
EGCG elevates wild-type cTnI expression in a cTnI-R193H mouse model of restrictive cardiomyopathy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 376-382.
|
[11] |
CHEN Miao, ZHANG Xinjin, MENG Hongli, YANG Bei, SONG Lijuan, ZOU Chuannan, GUAN Yingxia.
Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 451-457.
|
[12] |
SHEN Lei, WANG Keke, YANG Jingke, ZHAO Juntao, MENG Xiangguang, YUAN Yiqiang.
Advances in drugs and genetic pharmacology for heart failure
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 343-349.
|
[13] |
XU Shengsong, TAO Hui, SHI Kaihu, DING Jifei.
Expression and clinical significance of EZH2 and α-SMA in myocardium of patients with rheumatic heart disease with atrial fibrillation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1371-1375.
|
[14] |
WANG Kaiyang, LI Xiaoli, CAI Yongqing.
Research progress of endoplasmic reticulum stress in heart diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1310-1314.
|
[15] |
WANG Yang, DU Pei, GAO Keqin, YANG Shuang, JIA Sujie.
Effects of trichostatin A on CD14+ monocytes activation and TLR4 signal pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 867-873.
|